VRNA - רווח נקי למניה (EPS TTM) Verona Pharma PLC
A snapshot of the rolling net income per share helps assess the effectiveness of Verona Pharma plc (VRNA) strategic alliances for developing respiratory medications. Business resilience is bolstered by rigorous pharmaceutical logistics and patents for the Ensifentse drug used in COPD therapy. This indicator reveals hidden risks of developmental stagnation, with the metric currently standing at -1.04, eliminating mathematical reporting distortions.
Verona Pharma Corp - פילוחים אנליטיים ומדדי מפתח (VRNA)
Net income per share over twelve months measures the equity portion of the bottom line, allowing investors to filter out market volatility and assess the actual efficiency of the business. By analyzing the 12-month EPS trend, an investor can forecast the growth in value of Verona Pharma plc (VRNA), leveraging the high margins of Ohtuvayre, which is protected from generics by strict patent barriers and FDA approval.
